^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + bortezomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Published date:
10/29/2020
Excerpt:
In this randomised, double-blind, multicentre, phase 3 trial, patients aged 18 years or older with relapsed or refractory multiple myeloma…median progression-free survival according to independent review committee was 22·4 months (95% CI 15·3–not estimable) with venetoclax...The primary endpoint was met with a significant improvement in independent review committee-assessed progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone.
DOI:
10.1016/S1470-2045(20)30525-8
Trial ID:
